MedTrace Logo

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 760

Last updated 2026-04-07

No results posted yet for this study

Summary

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma

Conditions

Interventions

DRUG

Tremelimumab

Tremelimumab IV (intravenous)

DRUG

Durvalumab

Durvalumab IV (intravenous)

PROCEDURE

Transarterial Chemoembolization (TACE)

TACE (chemo and embolic agent injection into the hepatic artery)

DRUG

Lenvatinib

Lenvatinib (oral)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2026-02-23
Completion
2027-02-26
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Brazil
  • Canada
  • China
  • Egypt
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Malaysia
  • Mexico
  • Philippines
  • Portugal
  • Puerto Rico
  • Saudi Arabia
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05301842 on ClinicalTrials.gov